PHAR News

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

Taiwan Biotech Delegation Heads to BIO 2026 to Advance Global Partnerships and Innovation

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

Pharming Group announces results of 2026 Annual General Meeting of Shareholders

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders